Rodman & Renshaw Initiates Coverage On Leap Therapeutics with Buy Rating, Announces Price Target of $8
Leap Therapeutics, Inc. +15.28% Pre
Leap Therapeutics, Inc. LPTX | 4.15 4.15 | +15.28% 0.00% Pre |
Rodman & Renshaw analyst Tony Butler initiates coverage on Leap Therapeutics (NASDAQ:
LPTX) with a Buy rating and announces Price Target of $8.